Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Akebia Therapeutics reported Q3 2026 financial results, highlighted by a 140% year-over-year increase in patients on Vafseo to approximately 11,500. The company reported Vafseo net product revenues of $14.8 million and maintained a strong cash position of $159.3 million as it prepares for expanded market access in 2027.
Term
Q3 2026
“Our strategic commercial priority remains making Vafseo standard of care for the treatment of anemia for patients on dialysis, and we are focused on continuing to increase the number of patients on therapy.”
John P. Butler, Chief Executive Officer of Akebia
“We believe this compelling data has the potential to drive Vafseo to be standard of care. We continue to work to strengthen our market position as we enter 2027 when we believe Vafseo access will expand beyond the Transitional Drug Add-on Payment Adjustment (TDAPA)-only patients to nearly all clinically eligible patients.”
Appian Corp reported third quarter 2026 financial results with total revenue increasing 25% year-over-year to $234.6 million, driven by a 20% rise in cloud subscriptions revenue. The company achieved GAAP net income of $12.3 million ($0.17 per diluted share) and provided full-year 2026 revenue guidance of $873 million to $877 million.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on immunology and autoimmune diseases, specifically developing product candidates budoprutug and CLYM116. As of October 30, 2026, the company had 58,738,178 shares of common stock outstanding and continues to incur significant losses with no current source of product revenue.
Monte Rosa Therapeutics reported a net loss of $84.8 million for the nine months ended September 30, 2026, compared to a net income of $7.5 million in the prior year period, primarily due to lower collaboration revenue. The company significantly strengthened its balance sheet through an underwritten public offering that raised $323.8 million, ending the period with $577.7 million in cash, cash equivalents, and marketable securities.
ConocoPhillips reported Q3 2026 earnings of $4.0 billion ($3.34 per share) and adjusted earnings of $3.9 billion ($3.27 per share), driven by higher realized prices. The company increased its quarterly ordinary dividend by 11% to $0.93 per share and returned $3.4 billion to shareholders during the quarter, including $2.4 billion in share repurchases.
Term
Q3 2026
“ConocoPhillips is continuing to execute our differential strategy, with strong operational and financial performance across the portfolio. We’re capturing efficiencies across our best-in-class Lower 48 assets, growing our strategic commercial LNG offtake portfolio and advancing Willow critical path items.”
Andy O’Brien, president and chief executive officer
“Our differentiated value proposition, underpinned by the deepest, highest-quality upstream portfolio in the sector, positions us to deliver continued CFO and free cash flow growth at an advantaged reinvestment rate well into the next decade.”
Andy O’Brien, president and chief executive officer
Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.
“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”
John Shannon, Chairman and Chief Executive Officer
“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”
John Shannon, Chairman and Chief Executive Officer
Envoy Medical reported third quarter 2026 financial results and provided a clinical update on its Acclaim fully implanted cochlear implant. The company reached a six-month follow-up milestone for its full pivotal trial cohort and submitted the second module of its Modular PMA application to the FDA.
“We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as we approach an extremely exciting 2027. Not only did we report encouraging 12-month data from the first 10 participants in our trial, but we also surpassed the three-month follow-up mark for the full cohort. Since quarter end, we have now surpassed the six-month follow-up milestone. We remain on track for all participants to complete their 12-month visits by early in the second quarter of 2027. Each milestone brings us closer to offering cochlear implant candidates a fully implanted option they have wanted for decades.”
Brent Lucas, Chief Executive Officer of Envoy Medical
Certara reported third quarter 2026 financial results with revenue of $94.9 million, driven by 11% growth in software revenue. The company narrowed its full-year 2026 revenue growth guidance to 2-3% and appointed Grant Peterson as Chief Product Officer.
Term
3 months
“I am pleased with the steady progress we are making against our strategic, customer and operational objectives. We delivered solid revenue and profit in the quarter, and software revenue grew 11% organically, our first double-digit quarter in two years. We are focused on the disciplined execution required to deliver this performance consistently.”
Jon Resnick, Chief Executive Officer
“The third quarter reflects continued software momentum and the initial benefits of the operating actions we implemented in the first half. Adjusted EBITDA margin improved to 31.8%, up more than 370 basis points from the second quarter. We generated $30.7 million of cash from continuing operations in the quarter and ended with $214.9 million in cash. With nine months of results reported, we are narrowing our 2026 full year revenue growth range to 2% to 3%.”
Climb Bio reported Q3 2026 financial results, highlighting a cash position of $227.6 million which provides a runway into the second half of 2028. The company initiated dosing in its Phase 2 trial for CLYM116 in IgA nephropathy and reported positive Phase 1 data supporting a best-in-class every-12-week dosing profile.
Term
Q3 2026
“We are building significant momentum across our programs, CLYM116 and budoprutug. For CLYM116, two independent datasets support a best-in-class anti-APRIL profile and initial budoprutug data from our ongoing Phase 2 PrisMN study in primary membranous nephropathy demonstrated meaningful B-cell depletion and immunologic remission at 200 mg, with potential for increased activity at higher doses.”
Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer
“Looking ahead, we are poised to enter 2027 with two promising programs, multiple anticipated data readouts across both, and the potential to initiate pivotal studies.”
Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer
Zenas BioPharma reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of its BLA for obexelimab with a PDUFA date of May 27, 2027. The company ended the quarter with $647.1 million in cash and investments, which it expects will fund operations into 2027 as it prepares for potential commercialization.
Term
Q3 2026
“This quarter we continued to execute across our portfolio as we prepare for the potential commercialization of obexelimab for the treatment of IgG4-RD. Following the FDA’s acceptance of our BLA in the second quarter of this year, and the recent submission of our MAA to the EMA, we remain focused on commercial readiness ahead of the potential launch.”
Lonnie Moulder, Founder and Chief Executive Officer
“Across our broader pipeline, we remain on track to report topline Phase 2 SunStone data in SLE and initial Phase 1 data for our oral IL-17 inhibitor, ZB021, this quarter. We look forward to closing out a very productive year as we turn our attention to 2027 and continue to build toward our vision of becoming a fully integrated, global development and commercial-stage biopharmaceutical company.”
Lonnie Moulder, Founder and Chief Executive Officer
Evolent Health reported Q3 2026 revenue of $725.4 million, a significant increase from $479.5 million in the prior year, driven by strong demand for complex specialty care solutions and oncology launches. The company also announced a four-year renewal of its largest Surgical Management contract and two new oncology service expansions with national payers.
“As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us. That growth and demand from existing clients, as well as strong execution in our 2026 oncology launches, continue to drive strong performance in 2026. Looking ahead, I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come.”
Seth Blackley, Co-Founder and Chief Executive Officer of Evolent
Tripadvisor announced that CEO Matt Goldberg will depart his role effective February 16, 2027, following a Board determination that a leadership transition was in the company's best interests. Additionally, CFO Michael Noonan will resign effective December 31, 2026, to pursue another opportunity, with Kristen Dalton appointed as interim CFO starting January 1, 2027.
REGENXBIO reported Q3 2026 financial results, highlighting progress toward a BLA submission for its Duchenne muscular dystrophy gene therapy RGX-202 in Q1 2027. The company also expects topline pivotal data for its wet AMD candidate sura-vec in Q4 2026, with global regulatory submissions planned for 2027.
“We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028. With topline pivotal data expected this quarter, sura-vec has the potential to transform the treatment paradigm for a broad spectrum of patients with wet AMD. We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible. We remain focused on executing these near-term milestones and leveraging our fully integrated capabilities to deliver meaningful new treatment options for patients.”
Curran Simpson, President and Chief Executive Officer of REGENXBIO
Vistance Networks reported Q3 2026 net sales of $319.7 million and GAAP income from continuing operations of $54.7 million. Alongside the results, the company announced a new $100 million stock repurchase program and revised its full-year adjusted EBITDA guidance downward due to customer demand shifting into 2027.
“During the third quarter, we continued to make progress across our Vistance Networks business, supported by ongoing DOCSIS 4.0 deployments and adoption of our next-generation intelligent amplifiers. While memory chip pressures and customer deployment timing continue to impact near-term performance, we remain confident in the long-term demand for our products and opportunities to expand our portfolio. We are also pleased with the significant value we have returned to shareholders following the divestitures of our CCS and RUCKUS businesses. Including our recently announced $1.50 per share special distribution, we will have distributed $16.50 per share in 2026. As of October 30, 2026, we repurchased $225 million of stock under our existing stock repurchase programs. With a strong, debt-free balance sheet, we are well positioned to continue investing in our business and creating additional value.”
Chuck Treadway, President and Chief Executive Officer
“Aurora Networks delivered $320 million of revenue and $57 million of Adjusted EBITDA in the third quarter. This was generally aligned with our expectations as memory chip pricing and stranded costs were more than offset by a lower variable compensation. Looking ahead, we are revising our full-year adjusted EBITDA guidance to $180 million to $200 million, primarily resulting from customer demand being pushed out into 2027. We remain confident in the underlying demand for our products and are focused on managing costs, maintaining financial flexibility and positioning the business to capitalize on longer-term network upgrade opportunities.”
LCI Industries reported third quarter 2026 net sales of $992.5 million and net income of $50.1 million, with growth in adjacent industries and aftermarket sales helping to offset lower RV OEM demand. The company highlighted operating margin expansion and progress toward its pending all-stock merger with Patrick Industries, which is expected to close in the first half of 2027.
Term
Q3 2026
“Our third-quarter results reflect continued progress in improving profitability in a soft outdoor recreation market. Margin expansion and 6% growth in product content per unit contributed to our performance and position us to achieve our updated full-year outlook.”
Johnny Sirpilla, Interim Chief Executive Officer
“Our new product pipeline and the repair and replacement needs of the installed RV base provide opportunities to serve customers even as demand for new units remains constrained. We are also advancing toward the proposed merger with Patrick Industries, which we continue to expect to close in the first half of 2027.”
OpenText reported its first quarter fiscal year 2027 results, featuring total revenues of $1.237 billion and core cloud revenue growth of 11% year-over-year. The company also declared a quarterly cash dividend of $0.28 per share and highlighted a $1.0 billion debt refinancing completed after the quarter's end.
“Our first quarter reflects the strength of our core portfolio and the value we deliver for clients. As clients move to AI, they need trusted context and connected data for outcomes they can rely on. With Aviator AI agents infused across our core portfolio and a go-to-market model built around our clients' success, we are supporting them at every step of their AI journey.”
Ayman Antoun, OpenText CEO
“OpenText delivered strong performance in the first quarter of Fiscal 2027, supported by continued financial and operational discipline. Following the quarter, we completed a $1.0 billion debt refinancing and paid down $300 million in debt through a successfully completed tender offer, providing the Company with greater financial flexibility. The durability of our operating model enables us to execute our capital allocation priorities through the remainder of Fiscal 2027.”
Tecnoglass reported record third-quarter revenue of $310.6 million, a 19.2% year-over-year increase driven by strong growth in multi-family and commercial business. Net income was $22.8 million, though margins were pressured by elevated aluminum costs and a strong Colombian Peso. The company's backlog reached a record $1.43 billion, providing strong visibility into 2027.
Term
Q3 2026
“We were pleased to deliver record revenues in the third quarter, up 19% year-over-year, led by 31% growth in our multi-family and commercial business. Single-family residential revenues grew 17% year-over-year excluding the previously disclosed pre-buy activity in the second quarter, reflecting continued market share gains as we expand outside of Florida.”
José Manuel Daes, Chief Executive Officer of Tecnoglass
“Our backlog reached another record of $1.43 billion, extending our track record of sequential growth since 2021 and reflecting consistent execution on a growing pipeline of multi-family and commercial projects.”
Christian Daes, Chief Operating Officer of Tecnoglass
Cooper-Standard Holdings reported Q3 2026 sales of $708.6 million, a 1.9% increase year-over-year despite a decline in global light vehicle production. The company posted a net loss of $20.4 million, primarily driven by $19.2 million in restructuring charges, while securing $148.8 million in net new business awards during the quarter.
Term
Q3 2026
“We are continuing to leverage our strong customer relationships to book new business awards at a record pace, with overall average contribution margins consistent with our longer-term strategic plans and targets.”
Jeffrey Edwards, chairman and CEO, Cooper Standard
“While headwinds from commodity prices and general inflation remained greater than we had expected in the third quarter, we are working with our customers to refine our commercial agreements and accelerate the timing of cost recoveries wherever possible.”
Jeffrey Edwards, chairman and CEO, Cooper Standard
Wendy's reported third-quarter 2026 results with revenues of $547.0 million and net income of $15.1 million. The company launched 'Dave’s Way,' a multi-year strategy focused on growing customer traffic and market share, and signed a letter of intent to acquire up to 163 restaurants from Meritage Hospitality Group.
Term
Q3 2026
“Dave’s Way brings our areas of focus together in one integrated strategy with a clear objective: growing customer traffic and market share while strengthening restaurant profitability. While there is significant work ahead, I’m pleased with our early progress, including testing enhancements to our menu, improving marketing execution and accelerating our digital business.”
Bob Wright, President and Chief Executive Officer
“We have evaluated the investment needs of Dave’s Way and are confident we have the financial capacity to execute the strategy. With approximately $413 million in cash and $174 million of free cash flow year-to-date, we are well positioned to invest in our Dave’s Way strategy.”
Steve Cirulis, Chief Financial Officer and Chief Strategy Officer
1stdibs.com reported Q3 2026 financial results with net revenue of $23.1 million, up 5% year-over-year, and its fourth consecutive quarter of positive Adjusted EBITDA. The company also announced a leadership transition where CEO David Rosenblatt will become Executive Chairperson on January 1, 2027, succeeded by current CPO/CMO Bradford Shellhammer. Additionally, the Board authorized a new $5.0 million share repurchase program.
Term
Q3 2026
“The third quarter was another quarter of product-driven improvement in our operating metrics. Orders grew year over year for the first time since the fourth quarter of 2024, and GMV grew 4% despite continued softness in the high-end furniture market. We believe this performance reflects share gains as our product improvements reach more buyers. We see a large opportunity ahead, and we are focused on capturing it.”
David Rosenblatt, Chief Executive Officer of 1stDibs
“We delivered our fourth consecutive quarter of positive Adjusted EBITDA in the third quarter. We remain focused on expense discipline while investing in the product and engineering work behind our roadmap.”
Ironwood Pharmaceuticals reported Q3 2026 total revenue of $133 million and GAAP net income of $60 million, driven by strong LINZESS U.S. net sales of $325 million. Due to strong performance, the company raised its full-year 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion and total revenue guidance to $485 - $510 million.
Counterparty
AbbVie Inc.
Term
Q3 2026
“Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cash flows. We believe LINZESS is on its way to returning to blockbuster status for 2026 with year-to-date U.S. net sales already surpassing total 2025 U.S. net sales, primarily driven by improved net price and mid-single-digit prescription demand growth.”
Tom McCourt, Ironwood Chief Executive Officer
“In addition to driving strong financial performance, we are ramping up the STARS-2 confirmatory Phase 3 trial of apraglutide in people living with short bowel syndrome with intestinal failure. As we continue to add trial sites in the U.S., all of the planned clinical trial applications have been submitted to international health authorities and are now under review or already approved.”
GPGI, Inc. reported its third quarter 2026 financial results and declared a quarterly cash dividend of $0.0025 per share. The company also provided an investor presentation to accompany the earnings release, detailing its operational performance for the three and nine months ended September 30, 2026.
Zoetis reported third-quarter 2026 revenue of $2.4 billion, a 1% decrease compared to the prior year, driven by macro-driven price sensitivity and competitive pressure in the U.S. companion animal segment. The company narrowed its full-year 2026 revenue guidance and raised its adjusted EPS guidance, citing confidence in its innovation pipeline and livestock growth.
Term
Q3 2026
“Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio.”
Kristin Peck, Chief Executive Officer of Zoetis
“We remain focused on defending our position and directing our resources where they can have the greatest impact. And with the scale, expertise, and pipeline to keep setting the pace of innovation in animal health, we are confident in our ability to create long-term value for customers and shareholders.”
Six Flags Entertainment Corporation reported Q3 2026 net revenues of $1.17 billion, an 11% decrease on a reported basis but a 1.4% increase on a same-park basis. The company recorded a net loss of $366.1 million, which included $687.7 million in non-cash impairment charges. Management highlighted a 36.5% year-to-date increase in operating cash flow and total liquidity of $1.06 billion.
CareCloud reported its most profitable quarter in company history for Q3 2026, achieving record GAAP net income of $4.7 million and record adjusted EBITDA of $9.9 million. Revenue grew 9% year-over-year to $33.7 million, driven by AI-powered healthcare technology and revenue cycle management solutions.
Tripadvisor reported third quarter 2026 financial results, showing an 11% revenue decline to $436.4 million. The company recorded a significant GAAP net loss of $316.9 million, primarily driven by a $369.5 million non-cash goodwill impairment charge. On a non-GAAP basis, the company remained profitable with net income of $43.4 million.
Latigo Biotherapeutics reported Q3 2026 financial results, ending the period with $401 million in cash to fund operations into 2029. The company also announced the appointment of Todd Smith as President and CEO, replacing Nima Farzan, and updated its Phase 3 onzotrigine trial design to include a Percocet comparator arm.
Term
Q3 2026
“With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program.”
Todd N. Smith, president and chief executive officer
Genesis Energy reported Q3 2026 net income of $2.4 million and Adjusted EBITDA of $130.5 million, with results slightly exceeding internal expectations. The company maintained its quarterly distribution at $0.20 per common unit, representing a 21% increase year-over-year, while reporting a bank leverage ratio of 5.03X.
Term
Q3 2026
“Our third quarter results came in modestly ahead of our internal expectations. Our Offshore Pipeline Transportation segment experienced no disruptions of throughput from weather-related producer shut-ins during what is typically the most active part of hurricane season.”
Grant Sims, CEO of Genesis Energy
“Following the significant financing activity in the first half of the year, there is little to report on the balance sheet this quarter. We ended the quarter with no borrowings outstanding under our $900 million senior secured credit facility, approximately $41.5 million of unrestricted cash on hand, no debt maturities until 2029, and a bank-calculated leverage ratio of approximately 5.03x.”
Orion Energy Systems reported Q2 FY2027 revenue of $21.7M, a 9% increase year-over-year, driven by a 40% surge in LED lighting revenue. Despite the revenue growth, the company reported a net loss of $0.8M and reiterated its full-year revenue guidance of $100M-$102M.
Term
Q2 2027
“Orion enters the second half of FY’27 accelerating our initiatives to achieve diversified growth, sustainable margins and market expansion. Whether it’s rapidly growing engagements with major retail chains and logistics leaders, more and more campuses for hyper-scale data-center operators or expanding incumbencies with global automakers, Orion continues on a trajectory to achieve our profitable growth expectations for the current fiscal year.”
Acacia Research reported Q3 2026 total revenue of $54.4 million, an 8% decrease year-over-year primarily due to lower intellectual property license revenue. The company posted a GAAP net loss of $5.6 million but achieved positive Adjusted EBITDA of $3.9 million and ended the quarter with $346.3 million in cash and liquid assets.
“In the third quarter, Acacia generated total revenue of $54.4 million. Our total revenue excluding our Intellectual Property Operations of $54.2 million increased for the third consecutive quarter and was a near record. We also delivered Operated Segment Adjusted EBITDA of $9.1 million and Total Company Adjusted EBITDA of $3.9 million.”
Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer
“We ended the quarter with approximately $346.3 million, or $3.55 per share, in cash, equity securities and loans receivable, up from $3.43 per share last quarter, with no parent-company debt. With an active acquisition pipeline and a flexible investment mandate, we remain focused on compounding long-term intrinsic value per share through disciplined capital allocation.”
Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer